Dr. Michael Ferguson is an Assistant Professor of Pediatrics and Medical Director of the Pediatric Cancer Precision Genomics Program. He received his medical degree from Indiana University and completed Residency and Fellowship at Riley Hospital for Children, while also obtaining his master’s degree in Clinical Investigation. His research is currently focused on finding new agents for the treatment of relapsed sarcomas (specifically rhabdomyosarcoma, osteosarcoma, and Ewings sarcoma).
Därr R, Nambuba J, Del Rivero J, Janssen I, Merino M, Todorovic M, Balint B, Jochmanova I, Prchal JT, Lechan RM, Tischler AS, Popovic V, Miljic D, Adams KT, Prall FR, Ling A, Golomb MR, Ferguson M, Nilubol N, Chen CC, Chew E, Taïeb D, Stratakis CA, Fojo T, Yang C, Kebebew E, Zhuang Z, Pacak K. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocr Relat Cancer. 2016 Dec;23(12):899-908. Epub 2016 Sep 27.
Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR; REiNS International Collaboration. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology. 2016 Aug 16;87(7 Suppl 1):S40-8
Ferguson MJ, Rhodes, SJ, Jiang L, Li X, Yuan J, Yang X, Zhang S, Vakili ST, Territo P, Hutchins GD, Yang FC, Clapp DW, Chen S. Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas. Pediatric Blood Cancer. 2016 Feb;63(2):206-13.
Ferguson MJ, Hingorani P, Gupta AA. Emerging Molecular-Targeted Therapies in Early-Phase Clinical Trials and Preclinical Models. What’s New and Improved in the Care of Children with Rhabdomyosarcoma? ASCO 2013. Educational Book 420-424
Egbelakin A, Ferguson MJ, Macgill EA, Lehmann AS, Topletz AR, Quinney SK, Li L, McCammack KC, Hall SD, Renbarger JL. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011 Mar;56(3): 361-7
Kevin M. Sheridan, Michael J. Ferguson, Matthew R. Distasi, Frank A. Witzmann, Michael C. Dalsing, Steven J Miller, Joseph L. Unthank. Impact of genetic background and aging on mesenteric collateral growth capacity in Fischer 344, Brown Norway, and Fischer 344-Brown Norway hybrid rats. American Journal of Physiology-Heart and Circulatory Physiology. 2007 Dec; 293(3): H3498-3505.
McKee EE, Ferguson M, Bentley AT, Marks, TA. Inhibition of Mammalian Mitochondrial Protein Synthesis by Oxazolidinones. Antimicrobial Agents and Chemotherapy 50: June 2006
Titles & Appointments
- Associate Professor of Clinical Pediatrics
- Medical Director, Pediatric Cancer Precision Genomics Program